| Oxacillin-resistant Staphylococcus aureus (ORSA) or methicillin-resistant Staphylococcus aureus (MRSA) his become an important nosocomial pathogen in many countries. Vancomycin is currently the treatment of choice for serious infections caused by ORSA. However, with the emergence of these resistant isolates to vancomycin and other glycopeptides underscores the need other drugs that can provide an alternative antimicrobial agents for treatment of multi-drug-resistant S. aureus. The aim of the research is to monitor the effectiveness of Vancomycin and other antibiotics for infection caused by S. aureus. During May 18, 2000 to September 22, 2003 specimens were collected from patients at Atmajaya Hospital. The bacterial isolates were identified with biochemical reaction using Microbact and susceptibility tests were performed by a standard NCCLS method. Sixty-one S. aureus were isolated from many specimen and restricted into several categories: (i) ORSA (29 strains), the group included ORSA-VRSA (26 strains) and ORSA-VSSA (3 strains); (it) nonORSA, the group included nonORSA-VRSA (30 strains) and nonORSA-VSSA (2 strains). ORSA-VRSA were multi-resistant to antibiotics. However, only meropenem was the choice for the infection caused by these group of ORSA-VRSA bacteria. ORSA-VSSA also were multi-resistant to antibiotics and vancomycin was sensitively intermediate instead. Both nonORSA and VRSA, as well as VSSA, are multi-sensitive to antibiotics especially to cephalosporin. In conclusion, if S. aureus have already resistant to oxacillia and vancomycin (ORSA-VRSA), they also will have developed other resistance to other antimicrobial drugs, so it will more difficult to treat Infection caused by ORSA-VRSA. |